← Leaderboards
Sandra D. Comer
New York State Psychiatric Institute
$36,146,642
Attributed
$62,918,976
Total exposure
20
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $11.6M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$62,918,976 · 20
By mechanism
UG3$32,817,964 · 6
R01$16,580,863 · 8
UH3$9,673,869 · 3
P50$2,245,817 · 1
U54$1,182,497 · 1
R21$417,966 · 1
Top collaborators
- Marco Pravetoni6 shared
- Adam Mariusz Bisaga4 shared
- Alonso Guedes3 shared
- Howard Levin3 shared
- Gebhard Wagener3 shared
- Gretchen L Snyder2 shared
- Dean Foster Wong2 shared
- Kevin B. Freeman1 shared
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsOpioidDoseHeroinResponseNaloxoneBuprenorphineDesignSafetyParticipantLaboratoriesClinical ResearchMorphinePlacebosFundingOpioid AbuseAgonistMethadoneDrug UsageGrantOpioid ReceptorSelf AdministrationPrescription OpioidEffectiveness
Grant awards (53)
MEB-1170: A New Chemical Entity for the Treatment of Opioid Use Disorder$4,710,576
UG3 · FY2025 · DA
Development of a monoclonal antibody to reverse overdose from fentanyl and its analogs: from manufacturing to clinical trials$3,410,308
UH3 · FY2025 · DA
Transcutaneous Phrenic Nerve Stimulation for Treating Opioid Overdose$2,544,126
UH3 · FY2025 · DA
Transcutaneous Phrenic Nerve Stimulation for Treating Opioid Overdose$149,883
UH3 · FY2025 · DA
Phase 1a/1b Clinical Trials of Multivalent Opioid Vaccine Components$3,569,552
UH3 · FY2023 · DA · contact PI
Transcutaneous Phrenic Nerve Stimulation for Treating Opioid Overdose$927,319
UG3 · FY2023 · DA
Development of a monoclonal antibody to reverse overdose from fentanyl and its analogs: from manufacturing to clinical trials$8,267,350
UG3 · FY2022 · DA
Phase 1 and 2 studies of sublingual dexmedetomidine, an alpha 2 adrenergic agonist, for treating opioid withdrawal$3,312,204
UG3 · FY2022 · DA
Development of ITI-333, a μ-opioid Receptor Partial Agonist and 5HT2A and D1 Receptor Antagonist, for the Treatment of Opioid Use Disorders$2,917,074
UG3 · FY2021 · DA
Phase 1a/1b Clinical Trials of Multivalent Opioid Vaccine Components$3,788,472
UG3 · FY2019 · DA · contact PI
Development of ITI-333, a μ-opioid Receptor Partial Agonist and 5HT2A and D1 Receptor Antagonist, for the Treatment of Opioid Use Disorders$3,249,130
UG3 · FY2019 · DA
Phase 1a/1b Clinical Trials of Multivalent Opioid Vaccine Components$1,524,758
UG3 · FY2019 · DA · contact PI
Phase 1a/1b Clinical Trials of Multivalent Opioid Vaccine Components$4,121,081
UG3 · FY2018 · DA · contact PI
Medication Development for Opioid and Alcohol Abuse: Laboratory Studies in Humans$618,643
R01 · FY2018 · DA · contact PI
Risk and Benefits of Overdose Education and Naloxone Prescribing to Heroin Users$536,836
R01 · FY2018 · DA · contact PI
Medication Development for Opioid and Alcohol Abuse: Laboratory Studies in Humans$631,728
R01 · FY2017 · DA · contact PI
Risk and Benefits of Overdose Education and Naloxone Prescribing to Heroin Users$534,195
R01 · FY2017 · DA · contact PI
CERC-501 Kappa Antagonist for Nicotine Dependence$1,020,517
R01 · FY2016 · DA
Risk and Benefits of Overdose Education and Naloxone Prescribing to Heroin Users$531,170
R01 · FY2016 · DA · contact PI
Dynamic Contrast-Enhanced MRI to Measure Blood-Brain Barrier Permeability in Substance Abusers$204,205
R21 · FY2016 · DA · contact PI
Project 3: Laboratory: Pharmacotherapies for Opioid Use Disorder$610,451
U54 · FY2015 · DA · contact PI
Risk and Benefits of Overdose Education and Naloxone Prescribing to Heroin Users$533,687
R01 · FY2015 · DA · contact PI
Dynamic Contrast-Enhanced MRI to Measure Blood-Brain Barrier Permeability in Substance Abusers$213,761
R21 · FY2015 · DA · contact PI
Prescription Opioid Effects in Drug and Non-drug Abusers$581,048
R01 · FY2014 · DA · contact PI
Project 3: Laboratory: Pharmacotherapies for Opioid Use Disorder$572,046
U54 · FY2014 · DA · contact PI
Risk and Benefits of Overdose Education and Naloxone Prescribing to Heroin Users$540,495
R01 · FY2014 · DA · contact PI
Pioglitazone for the Treatment of Opioid and of Nicotine Dependence$833,527
R01 · FY2013 · DA · contact PI
Prescription Opioid Effects in Drug and Non-drug Abusers$571,584
R01 · FY2013 · DA · contact PI
Pioglitazone for the Treatment of Opioid and of Nicotine Dependence$889,448
R01 · FY2012 · DA · contact PI
Prescription Opioid Effects in Drug and Non-drug Abusers$599,844
R01 · FY2012 · DA · contact PI
Pioglitazone for the Treatment of Opioid and of Nicotine Dependence$877,017
R01 · FY2011 · DA · contact PI
Prescription Opioid Effects in Drug and Non-drug Abusers$603,680
R01 · FY2011 · DA · contact PI
Pioglitazone for the Treatment of Opioid and of Nicotine Dependence$870,800
R01 · FY2010 · DA · contact PI
Prescription Opioid Effects in Drug and Non-drug Abusers$607,159
R01 · FY2010 · DA · contact PI
Sustained-Release Naltrexone for Opioid Dependence: Longitudinal Study in Humans$307,327
R01 · FY2010 · DA · contact PI
Sustained-Release Naltrexone for Opioid Dependence: Longitudinal Study in Humans$307,369
R01 · FY2009 · DA · contact PI
Laboratory Model for Heroin Abuse Medications$545,582
P50 · FY2008 · DA · contact PI
Laboratory Model for Heroin Abuse Medications$586,313
P50 · FY2007 · DA · contact PI
Precription Opioid Effects in Drug and Non-drug Abusers$414,936
R01 · FY2007 · DA · contact PI
Precription Opioid Effects in Drug and Non-drug Abusers$415,567
R01 · FY2006 · DA · contact PI
Laboratory Model for Heroin Abuse Medications$388,937
P50 · FY2006 · DA · contact PI
Sustained-Release Naltrexone for Opioid Dependence: Longitudinal Study in Humans$319,894
R01 · FY2006 · DA · contact PI
Precription Opioid Effects in Drug and Non-drug Abusers$416,886
R01 · FY2005 · DA
Laboratory Model for Heroin Abuse Medications$355,606
P50 · FY2005 · DA
Precription Opioid Effects in Drug and Non-drug Abusers$402,527
R01 · FY2004 · DA
Laboratory Model for Heroin Abuse Medications$369,379
P50 · FY2004 · DA
Precription Opioid Effects in Drug and Non-drug Abusers$401,370
R01 · FY2003 · DA
PAIN AND ANALGESIC RESPONSE--SEX AND HORMONE VARIATIONS$398,620
R01 · FY2002 · DE
BUPRENORPHINE ABUSE BY HUMANS--LABORATORY STUDIES$363,410
R01 · FY2002 · DA
PAIN AND ANALGESIC RESPONSE--SEX AND HORMONE VARIATIONS$387,889
R01 · FY2001 · DE
BUPRENORPHINE ABUSE BY HUMANS--LABORATORY STUDIES$353,207
R01 · FY2001 · DA
PAIN AND ANALGESIC RESPONSE--SEX AND HORMONE VARIATIONS$367,462
R01 · FY2000 · DE
BUPRENORPHINE ABUSE BY HUMANS--LABORATORY STUDIES$343,021
R01 · FY2000 · DA